The investment is part of Revera’s Innovators in Aging Program and will help scale and distribution of the geko™ wound-healing device piloted at Revera long term care homes across Canada
MISSISSAUGA, Canada, July 17, 2017 - In line with its commitment to bring the most promising innovations to Canadian seniors, Revera has invested £500,000 (approximately $820,000 CAD) in Sky Medical Technology, a U.K.-based health technology company and makers of the geko™ device, an aid in the treatment of hard-to-heal wounds.
“New technologies have the potential to enhance the experience and quality of life of our residents. This is why Revera created the Innovators in Aging program as a platform to test, scale and invest in innovations that could truly help seniors age well.” says Trish Barbato, Senior Vice President of Innovation and Strategic Partnerships at Revera. “Revera tested the geko™ device with long term care residents who had chronic, hard-to-heal wounds and saw positive outcomes. As a result, we are investing in Sky Medical to help support its further growth.”
Sky Medical Technology’s self-adhesive electro-stimulation geko™ device is designed to help treat hard-to-heal wounds by enhancing blood circulation and preventing blood clotting. The device also provides treatment for ischemia (a restriction in blood supply), poor blood flow and swelling.
Chronic wounds such as venous, diabetic and arterial ulcers can be hard to heal, particularly in older adults who often have underlying health conditions. In addition to affecting quality of life, if not treated effectively, these types of wounds can lead to infection, reduced mobility and even the loss of a limb.
In 2016, Revera began piloting the geko™ device with select long term care residents who had non-healing wounds in their lower extremities. The device was effective in closing wounds, reducing pain and swelling and improving quality of life.
“The opportunity to pilot the geko™ device at Revera’s long term care homes has been invaluable to the development of this technology,” says CEO Bernard Ross, Sky Medical Technology. “We were thrilled to see how the device assisted the seniors in their recovery and hope to bring it to more older adults in need of help.”
Revera’s pilot of the geko™ device served as the product’s international launch in the senior care space. Through the program, Sky Medical Technology was able to test the geko™ device and receive feedback from both residents and staff in real-time.
The geko™ device is one of a number of products and services piloted at Revera retirement communities and long term care homes as part of the company’s Innovators in Aging Program, through which Revera intends to invest up to $20 million over five years to help bring the most promising products, services and technologies to the seniors who need them most. As it moves forward with this program, Revera will continue to partner with promising entrepreneurs to bring new technologies that will help improve the lives of its residents.
About Revera Inc.
Revera is a leading owner, operator and investor in the senior living sector. Through its portfolio of partnerships, Revera owns or operates more than 500 properties across Canada, the United States and the United Kingdom, serving more than 50,000 seniors. The company offers seniors’ apartments, independent living, assisted living, memory care and long term care. With approximately 45,000 employees dedicated to providing exceptional care and service, Revera is helping seniors live life to the fullest. Through Age is More, Revera is committed to challenging ageism, the company’s social cause of choice. Find out more at ReveraLiving.com
, Facebook.com/Revera Inc
or on Twitter @Revera_Inc
About Sky Medical Technologies
Sky Medical Technology, parent company of Firstkind Ltd, is a UK based medical devices company that has developed a ground-breaking neuromuscular electrostimulation platform, OnPulse™. The company develops a range of products tailored to different medical applications, selling both direct, through partnerships or distributors in each clinical area. Clinical areas of interest include wound healing, DVT prevention, reduction of swelling, elite-sport recovery, and continence. The goal in each clinical area is to improve clinical outcomes and patient care whilst saving health system resources. The geko™ device has secured National Institute of Clinical Excellence (NICE) guidance recommending its use to the NHS for DVT prevention, and US FDA clearance for USA market entry.
For further information please contact: